International stem cell tourism and the need for effective regulation. Part II: Developing sound oversight measures and effective patient support

Kennedy Inst Ethics J. 2010 Sep;20(3):207-30. doi: 10.1353/ken.2010.0001.


Part I of this article, published in the March 2010 issue of the Kennedy Institute of Ethics Journal, traces and addresses the provision of unproven stem cell treatments in Russia and India, examines the concept of innovative treatment, and concludes that stronger regulations are needed to protect the health and informed choices of patients. The current paper, Part II, proposes that the regulatory frameworks for the development of safe and efficacious treatments in effect in the United States and the United Kingdom provide examples of strong oversight measures from which countries seeking to obtain international credibility for their biotechnological competence could draw when developing regulations for stem cell treatments. Major sources of information available to persons who consider receiving such unproven treatments are explored in order to understand and address their concerns. The paper concludes with proposed measures to inform those considering the pursuit of unproven stem cell treatments abroad more accurately about their efficacy and safety and provide them with improved medical and social support in their home countries.

MeSH terms

  • Biotechnology / ethics
  • Biotechnology / legislation & jurisprudence*
  • Continuity of Patient Care
  • Humans
  • India
  • International Cooperation*
  • Medical Tourism / ethics
  • Medical Tourism / legislation & jurisprudence*
  • Russia
  • Social Support
  • Stem Cell Transplantation / ethics
  • Stem Cell Transplantation / legislation & jurisprudence*
  • United Kingdom
  • United States